Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:ARAVOTCMKTS:HBPCFNASDAQ:KZIANASDAQ:MACK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$4.40$45.72M2.2482,013 shs63,385 shsARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$31.81M-0.131 shsN/AKZIANovogen$6.82+3.7%$5.29$2.86▼$79.00$6.80M2.64387,300 shs294,323 shsMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-25.70%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%HBPCFHelix Biopharma0.00%0.00%0.00%+31.90%+335.73%KZIANovogen0.00%+7.59%+27.73%+91.87%-35.13%MACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AKZIANovogen2.0609 of 5 stars3.52.00.00.00.60.00.0MACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 0.00N/AN/AN/AARAVARAVIVE 0.00N/AN/AN/AHBPCFHelix Biopharma 0.00N/AN/AN/AKZIANovogen 3.00Buy$57.50742.98% UpsideMACKMerrimack Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARAV, MACK, HBPCF, KZIA, and ALRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AARAVARAVIVE$9.14M0.32N/AN/AN/A∞HBPCFHelix BiopharmaN/AN/AN/AN/A($0.02) per shareN/AKZIANovogen$1.51M4.56N/AN/A($9.87) per share-0.69MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/AARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/AHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%N/AKZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/AMACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/ALatest ARAV, MACK, HBPCF, KZIA, and ALRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30ARAVARAVIVEN/AN/AN/AHBPCFHelix BiopharmaN/A0.420.99KZIANovogenN/A0.21N/AMACKMerrimack PharmaceuticalsN/A10.7810.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%ARAVARAVIVE35.80%HBPCFHelix BiopharmaN/AKZIANovogen30.89%MACKMerrimack Pharmaceuticals63.97%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%ARAVARAVIVE60.40%HBPCFHelix Biopharma7.60%KZIANovogen1.00%MACKMerrimack Pharmaceuticals30.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableARAVARAVIVE2073.56 million29.13 millionNo DataHBPCFHelix Biopharma953.02 million48.99 millionNot OptionableKZIANovogen121.01 million997,000OptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableARAV, MACK, HBPCF, KZIA, and ALRN HeadlinesRecent News About These CompaniesMerrimack Pharma Stock Price HistoryJune 4, 2025 | investing.comEaston Daneault commits to MerrimackOctober 11, 2024 | themackreport.comTLife science trade group’s five-year vision includes further support for a diversified workforceOctober 10, 2024 | baystatebanner.comBNovel Drug Delivery Systems in Cancer Therapy Market Set to Reach USD 54.8 Billion by 2034 at a 10.8% of CAGROctober 10, 2024 | fmiblog.comFPro-Palestinian protesters found guilty of criminal trespassing for demonstration outside Merrimack facilityOctober 3, 2024 | wmur.comWZalc's field goal in final seconds gives Dartmouth 16-14 victory over MerrimackSeptember 30, 2024 | espn.comCollege football connection: Easton’s Hutchison posts 2 TDs in F&M victorySeptember 25, 2024 | msn.comPittsfield police issue fraud alert after skimming device found at local Cumberland FarmsSeptember 15, 2024 | newportdispatch.comWoman pepper sprays, kicks officer in stomach during arrest at Merrimack Outlets, police sayAugust 13, 2024 | wmur.comWFort Cumberland, Funkstown meet in playoff todayJuly 22, 2024 | times-news.comTMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | investorplace.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | msn.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMACK Merrimack Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comFrom debilitating disease to the marathonApril 14, 2024 | eagletribune.comEDiagonal starts up with $128M to make better ‘activator’ antibody drugsApril 3, 2024 | finance.yahoo.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 27, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARAV, MACK, HBPCF, KZIA, and ALRN Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.ARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 07/3/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 07/3/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Novogen NASDAQ:KZIA$6.82 +0.24 (+3.66%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$6.72 -0.11 (-1.55%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Merrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
